↓ Skip to main content

A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults

Overview of attention for article published in BMC Pulmonary Medicine, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
5 X users
wikipedia
1 Wikipedia page
f1000
1 research highlight platform

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
145 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults
Published in
BMC Pulmonary Medicine, May 2016
DOI 10.1186/s12890-016-0242-0
Pubmed ID
Authors

James D. Chalmers, James Campling, Alison Dicker, Mark Woodhead, Harish Madhava

Abstract

Invasive pneumococcal disease (IPD) and pneumococcal pneumonia are common and carry a significant morbidity and mortality. Current strategies to prevent pneumococcal disease are under review in the United Kingdom (UK). We conducted a systematic review to evaluate the burden of vaccine type adult pneumococcal disease specifically in the UK. A systematic review conducted and reported according to MOOSE guidelines. Relevant studies from 1990 to 2015 were included. The primary outcome was the incidence of vaccine type pneumococcal disease, focussing on the pneumococcal polysaccharide vaccine (PPSV), the 13-valent conjugate vaccine (PCV13) and the 7-valent conjugate vaccine (PCV7). Data from surveillance in England and Wales from 2013/14 shows an incidence of 6.85 per 100,000 population across all adult age groups for IPD, and an incidence of 20.58 per 100,000 population in those aged >65 years. The corresponding incidences for PCV13 serotype IPD were 1.4 per 100,000 and 3.72 per 100,000. The most recent available data for community-acquired pneumonia (CAP) including non-invasive disease showed an incidence of 20.6 per 100,000 for adult pneumococcal CAP and 8.6 per 100,000 population for PCV13 serotype CAP. Both IPD and CAP data sources in the UK suggest an ongoing herd protection effect from childhood PCV13 vaccination causing a reduction in the proportion of cases caused by PCV13 serotypes in adults. Despite this, applying the incidence rates to UK population estimates suggests more than 4000 patients annually will be hospitalised with PCV13 serotype CAP and more than 900 will be affected by IPD, although with a trend for these numbers to decrease over time. There was limited recent data on serotype distribution in high risk groups such as those with chronic respiratory or cardiac disease and no data available for vaccine type (VT) CAP managed in the community where there is likely to be a considerable unmeasured burden. The most recent available data suggests that VT pneumococcal disease continues to have a high burden in UK adults despite the impact of childhood PCV13 vaccination. IPD estimates represent only a fraction of the total burden of pneumococcal disease. PROSPERO CRD42015025043.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Portugal 1 <1%
Unknown 143 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 15%
Student > Master 17 12%
Student > Ph. D. Student 16 11%
Student > Bachelor 15 10%
Other 8 6%
Other 26 18%
Unknown 41 28%
Readers by discipline Count As %
Medicine and Dentistry 50 34%
Nursing and Health Professions 11 8%
Immunology and Microbiology 8 6%
Agricultural and Biological Sciences 7 5%
Biochemistry, Genetics and Molecular Biology 5 3%
Other 15 10%
Unknown 49 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2020.
All research outputs
#4,034,925
of 22,876,619 outputs
Outputs from BMC Pulmonary Medicine
#271
of 1,923 outputs
Outputs of similar age
#64,854
of 309,587 outputs
Outputs of similar age from BMC Pulmonary Medicine
#8
of 41 outputs
Altmetric has tracked 22,876,619 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,923 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.